BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Kapoor S, Champion G, Basu A, Mariampillai A, Olnes MJ. Immune Therapies for Myelodysplastic Syndromes and Acute Myeloid Leukemia. Cancers (Basel) 2021;13:5026. [PMID: 34638510 DOI: 10.3390/cancers13195026] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
Number Citing Articles
1 Mebarki S, Pamoukdjian F, Pierro M, Poisson J, Baldini C, Widad Lahlou, Taieb J, Fabre E, Canoui-Poitrine F, Oudard S, Paillaud E. Safety and efficacy of immunotherapy according to the age threshold of 80 years. Bull Cancer 2023:S0007-4551(23)00097-8. [PMID: 36894391 DOI: 10.1016/j.bulcan.2023.02.010] [Reference Citation Analysis]
2 Zhong M, Chen C, Zhao W, Tan J, Chen J, Huang X, Li Y, Dai M. High Co-Expression of PDCD1/TIGIT/CD47/KIR3DL2 in Bone Marrow Is Associated with Poor Prognosis for Patients with Myelodysplastic Syndrome. J Oncol 2023;2023:1972127. [PMID: 36816361 DOI: 10.1155/2023/1972127] [Reference Citation Analysis]
3 Gallazzi M, Ucciero MAM, Faraci DG, Mahmoud AM, Al Essa W, Gaidano G, Mouhssine S, Crisà E. New Frontiers in Monoclonal Antibodies for the Targeted Therapy of Acute Myeloid Leukemia and Myelodysplastic Syndromes. IJMS 2022;23:7542. [DOI: 10.3390/ijms23147542] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 6.0] [Reference Citation Analysis]